Anavex Life Sciences Corp (AVXL)

[Investor2014]

The resistance to accept the fact that one or more P3 confirmatory trials is required to gain full approval, even if a company decides to call a trial P2/3, is so strong that it prevents open minded logical thinking.

So much so that the prize of potential higher chances of AA out of the P2b/3 AD trial by Anavex proactively initiating a RCT P3 is overlooked and misunderstood.

It then uncovers fundamental misunderstandings of clinical trial phases and the purpose and issues that can be associated with P4 trials. All based on a desire to confirm a brilliant personal investment decision made out of stacks of ignorance around commercialisation magic of P4 trials.

Biotech investing is complicated and risky, but can be rewarding if willing to learn.